USP19 Human shRNA Plasmid Kit (Locus ID 10869)
CAT#: TR308463
USP19 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 6,790.00
货期*
2周
规格
Cited in 1 publication. |
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | USP19 Human shRNA Plasmid Kit (Locus ID 10869) |
Locus ID | 10869 |
UniProt ID | O94966 |
Synonyms | ZMYND9 |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | USP19 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 10869). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001199160, NM_001199161, NM_001199162, NM_006677, NM_001351098, NM_001351099, NM_001351100, NM_001351101, NM_001351102, NM_001351103, NM_001351104, NM_001351105, NM_001351106, NM_001351107, NM_001351108, NM_006677.1, NM_006677.2, NM_001199162.1, NM_001199161.1, NM_001199160.1, BC014934, BC048269, BC065909, BC082241, BC106029, BC128088, BC142660, BC142727, BC146752 |
Summary | Protein ubiquitination controls many intracellular processes, including cell cycle progression, transcriptional activation, and signal transduction. This dynamic process, involving ubiquitin conjugating enzymes and deubiquitinating enzymes, adds and removes ubiquitin. Deubiquitinating enzymes are cysteine proteases that specifically cleave ubiquitin from ubiquitin-conjugated protein substrates. This protein is a ubiquitin protein ligase and plays a role in muscle wasting. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2017] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer
,null,
OncoTargets and therapy
,PubMed ID 32904569
[USP19]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...